130 related articles for article (PubMed ID: 37897472)
1. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210).
Ferreras C; Hernández-Blanco C; Martín-Quirós A; Al-Akioui-Sanz K; Mora-Rillo M; Ibáñez F; Díaz-Almirón M; Cano-Ochando J; Lozano-Ojalvo D; Jiménez-González M; Goterris R; Sánchez-Zapardiel E; de Paz R; Guerra-García P; Queiruga-Parada J; Molina P; Briones ML; Ruz-Caracuel B; Borobia AM; Carcas AJ; Planelles D; Vicario JL; Moreno MÁ; Balas A; Llano M; Llorente A; Del Balzo Á; Cañada C; García MÁ; Calvin ME; Arenas I; Pérez de Diego R; Eguizábal C; Soria B; Solano C; Pérez-Martínez A
Cytotherapy; 2024 Jan; 26(1):25-35. PubMed ID: 37897472
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.
García-García I; Guerra-García P; Ferreras C; Borobia AM; Carcas AJ; Queiruga-Parada J; Vicario JL; Mirones I; Solano C; Eguizabal C; Soria B; Pérez-Martínez A
Trials; 2021 Oct; 22(1):674. PubMed ID: 34600562
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).
Pérez-Martínez A; Mora-Rillo M; Ferreras C; Guerra-García P; Pascual-Miguel B; Mestre-Durán C; Borobia AM; Carcas AJ; Queiruga-Parada J; García I; Sánchez-Zapardiel E; Gasior M; De Paz R; Marcos A; Vicario JL; Balas A; Moreno MA; Eguizabal C; Solano C; Arribas JR; Buckley RM; Montejano R; Soria B
EClinicalMedicine; 2021 Sep; 39():101086. PubMed ID: 34405140
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
6. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
7. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
8. Donor selection for adoptive cell therapy with CD45RA
Al-Akioui-Sanz K; Pascual-Miguel B; Díaz-Almirón M; Mestre-Durán C; Navarro-Zapata A; Clares-Villa L; Martín-Cortázar C; Vicario JL; Moreno MÁ; Balas A; De Paz R; Minguillón J; Pérez-Martínez A; Ferreras C
Cytotherapy; 2023 Mar; 25(3):330-340. PubMed ID: 36585293
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
Papadopoulou A; Karavalakis G; Papadopoulou E; Xochelli A; Bousiou Z; Vogiatzoglou A; Papayanni PG; Georgakopoulou A; Giannaki M; Stavridou F; Vallianou I; Kammenou M; Varsamoudi E; Papadimitriou V; Giannaki C; Sileli M; Stergiouda Z; Stefanou G; Kourlaba G; Gounelas G; Triantafyllidou M; Siotou E; Karaglani A; Zotou E; Chatzika G; Boukla A; Papalexandri A; Koutra MG; Apostolou D; Pitsiou G; Morfesis P; Doumas M; Karampatakis T; Kapravelos N; Bitzani M; Theodorakopoulou M; Serasli E; Georgolopoulos G; Sakellari I; Fylaktou A; Tryfon S; Anagnostopoulos A; Yannaki E
Nat Med; 2023 Aug; 29(8):2019-2029. PubMed ID: 37460756
[TBL] [Abstract][Full Text] [Related]
13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.
Ferreras C; Pascual-Miguel B; Mestre-Durán C; Navarro-Zapata A; Clares-Villa L; Martín-Cortázar C; De Paz R; Marcos A; Vicario JL; Balas A; García-Sánchez F; Eguizabal C; Solano C; Mora-Rillo M; Soria B; Pérez-Martínez A
Front Cell Dev Biol; 2021; 9():620730. PubMed ID: 33718360
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
17. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
19. Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial.
Cheng LL; Guan WJ; Duan CY; Zhang NF; Lei CL; Hu Y; Chen AL; Li SY; Zhuo C; Deng XL; Cheng FJ; Gao Y; Zhang JH; Xie JX; Peng H; Li YX; Wu XX; Liu W; Peng H; Wang J; Xiao GM; Chen PY; Wang CY; Yang ZF; Zhao JC; Zhong NS
JAMA Intern Med; 2021 Jan; 181(1):71-78. PubMed ID: 32910179
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
